سعر ابريبيمك 80 مجم 2 كبسولة 2022

Aprepitant 80 mg hard capsules, pack of 2 capsules (Eimc, Egypt); substance P/NK1 receptor antagonist antiemetic.

• Prevention, in combination with other antiemetic agents, of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC), including high-dose cisplatinPopulation: Adults and pediatric patients 12 years and older (capsules)DailyMed (U.S. National Library of Medicine)
• Prevention, in combination with other antiemetic agents, of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC)Population: Adults and pediatric patients 12 years and older (capsules)DailyMed (U.S. National Library of Medicine)

• Most common in pooled HEC/MEC trials (EMEND regimen vs standard therapy): fatigue 13%, diarrhea 9%, asthenia 7%, dyspepsia 7%, abdominal pain 6%, hiccups 5%, decreased white blood cell count 4%, dehydration 3%, increased ALT 3%. Hypersensitivity reactions including anaphylaxis have been reported.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Hypersensitivity to any component of the product (hypersensitivity reactions including anaphylaxis have been reported).International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Concurrent use with pimozide (CYP3A4 inhibition may raise pimozide levels, risking QT prolongation).International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Aprepitant is a CYP3A4 substrate, weak-to-moderate inhibitor and inducer: it can raise levels of CYP3A4 substrates; strong/moderate CYP3A4 inhibitors raise aprepitant levels and strong inducers (e.g. rifampin) lower its efficacy.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Co-administration with warfarin may cause a clinically significant decrease in INR.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Efficacy of hormonal contraceptives may be reduced during and for 28 days after the last dose; use effective alternative or back-up contraception during treatment and for 1 month afterwards.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• PimozideContraindicated: increased pimozide exposure (QT prolongation risk).DailyMed (U.S. National Library of Medicine)
• Dexamethasone (oral)Increased dexamethasone exposure; reduce the oral dexamethasone dose by approximately 50%.DailyMed (U.S. National Library of Medicine)
• MethylprednisoloneIncreased exposure; reduce IV methylprednisolone by about 25% and oral methylprednisolone by about 50%.DailyMed (U.S. National Library of Medicine)

• Insufficient data on use in pregnant women to inform a drug-associated risk; no adverse developmental effects in rats or rabbits at systemic exposures about 1.5 times the adult human exposure. Aprepitant crosses the placenta in rats and rabbits.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• No human lactation studies; aprepitant is present in rat milk. Weigh the benefits of breastfeeding against the mother's clinical need and potential adverse effects on the infant.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Aprepitant: Selective high-affinity antagonist of human substance P/NK1 receptors; crosses the blood-brain barrier and occupies brain NK1 receptors; little or no affinity for 5-HT3, dopamine or corticosteroid receptors.